<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Psychiatry</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Psychiatry</journal-id>
      <journal-title-group>
        <journal-title>BMC Psychiatry</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-244X</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24679075</article-id>
      <article-id pub-id-type="pmc">3976085</article-id>
      <article-id pub-id-type="publisher-id">1471-244X-14-93</article-id>
      <article-id pub-id-type="doi">10.1186/1471-244X-14-93</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Development of acute pancreatitis caused by sodium valproate in a patient with bipolar disorder on hemodialysis for chronic renal failure: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Okayasu</surname>
            <given-names>Hiroaki</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>hokayasu@dokkyomed.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes" id="A2">
          <name>
            <surname>Shinozaki</surname>
            <given-names>Takahiro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>tshinoz@dokkyomed.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes" id="A3">
          <name>
            <surname>Osone</surname>
            <given-names>Akira</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>osone@dokkyomed.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes" id="A4">
          <name>
            <surname>Ozeki</surname>
            <given-names>Yuji</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>ozeki@dokkyomed.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes" id="A5">
          <name>
            <surname>Shimoda</surname>
            <given-names>Kazutaka</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>shimoda@dokkyomed.ac.jp</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Psychiatry, Dokkyo Medical University, Mibu, Tochigi, Japan</aff>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>29</day>
        <month>3</month>
        <year>2014</year>
      </pub-date>
      <volume>14</volume>
      <fpage>93</fpage>
      <lpage>93</lpage>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>12</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>3</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 Okayasu et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder>Okayasu et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1471-244X/14/93"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Cases of acute pancreatitis caused by sodium valproate (VPA) have been reported by many authors thus far. However, most of these were cases with epilepsy. Chronic renal failure is also regarded as a risk factor for acute pancreatitis. Here, we report a case of acute pancreatitis development due to VPA in a patient with bipolar disorder on hemodialysis for chronic renal failure.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>The patient was a 52-year-old Japanese male who was diagnosed as bipolar disorder on hemodialysis for renal failure. He was treated with VPA and manic symptoms gradually stabilized. However, the patient complained of severe abdominal pain. Blood amylase was found to be markedly high, and computed tomography revealed pancreatomegaly and an increased amount of peripancreatic fat. Hence, we diagnosed the case as acute pancreatitis caused by VPA. We discontinued oral medication, and he was started on a pancreatic enzyme inhibitor, antibiotics, and transfusion, and he showed improvement.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>It has been reported that acute pancreatitis induced by VPA is caused by intermediate metabolites of VPA. We consider that patients with renal failure are prone to pancreatitis caused by VPA because of the accumulation of these intermediate metabolites. We need close monitoring for serious adverse effects such as pancreatitis when we prescribe VPA to patients with bipolar disorder on hemodialysis for chronic renal failure, although VPA is safer than other mood stabilizers.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Acute pancreatitis</kwd>
        <kwd>Sodium valproate</kwd>
        <kwd>Chronic renal failure</kwd>
        <kwd>Hemodialysis</kwd>
        <kwd>Bipolar disorder</kwd>
        <kwd>Mood stabilizer</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Acute pancreatitis is a rare, but serious and sometimes fatal, side effect of sodium valproate (VPA) administration. Hemodialysis for the treatment of chronic renal failure is also regarded as a risk factor for acute pancreatitis [<xref ref-type="bibr" rid="B1">1</xref>]. Here, we report our experience of a patient with bipolar disorder who developed acute pancreatitis caused by VPA administration while undergoing hemodialysis.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>The patient was a 52-year-old man who had proteinuria and hematuria that were diagnosed in his high-school days but for which he had not sought treatment. He subsequently experienced severe renal failure due to nephrosclerosis and was started on hemodialysis 2&#xA0;years before this case report. Thereafter, he had a depressive mood, anxiety, and insomnia, and he subsequently presented with symptoms such as pressure of speech, flight of ideas, delusions of grandeur, thought dispersion, and irritability. Diagnosis was bipolar disorder according to DSM-IV-TR diagnostic criteria, and he was treated with olanzapine but showed no improvement. He was admitted to the psychiatric ward of our university hospital.</p>
      <p>Because the patient continued to show a threatening attitude and irritability toward medical staff or other patients while being hospitalized, he was initially treated with VPA (400&#xA0;mg/day) in addition to olanzapine (10&#xA0;mg/day) and zopiclone (5&#xA0;mg/day) and other drugs for general medical conditions [nifedipine(40&#xA0;mg/day), artinolol hydrochloride (20&#xA0;mg/day), valsartan (160&#xA0;mg/day) and doxazosin mesilate (3&#xA0;mg/day) for hypertension, and sodium polystyrene sulfonate (25&#xA0;g/day) for hyperpotassemia, allopurinol (100&#xA0;mg/day) for hyperuricemia and alfacalcidol (0.25&#xA0;&#x3BC;g/day) for chronic renal failure] by the previous physician in charge. The dosage of VPA was increased up to 1,200&#xA0;mg/day, and the manic symptoms gradually stabilized. The plasma level of VPA was 88.5&#xA0;&#x3BC;g/ml.</p>
      <p>However, approximately 3&#xA0;weeks after increasing the dose of VPA to 1,200&#xA0;mg (62&#xA0;days after admission), the patient complained of severe abdominal pain. Blood amylase was found to be markedly high at 1,227 U/l (pancreatic amylase: 1,133 U/l) (Table&#xA0;<xref ref-type="table" rid="T1">1</xref>), and abdominal computed tomography revealed pancreatomegaly and an increased amount of peripancreatic fat (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>). Hence, acute pancreatitis was diagnosed. We believe that the pancreatitis was due to VPA because olanzapine, zopiclone and other drugs for general medical conditions had shown no particular adverse effects, and the patient had not consumed alcohol and did not have a history of biliary system disease such as gallstones. We promptly discontinued oral medication, and he was started on a pancreatic enzyme inhibitor, antibiotics, and transfusion, and he showed improvement for approximately 1&#xA0;month (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>). Because the patient&#x2019;s psychiatric symptoms were exacerbated, levomepromazine (50&#xA0;mg/day) was then started without any adverse effects. He was discharged on Day 197 of the illness.</p>
      <table-wrap position="float" id="T1">
        <label>Table 1</label>
        <caption>
          <p>Laboratory data at the time when acute pancreatitis was diagnosed</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="left">
                <bold>Laboratory parameters</bold>
              </th>
              <th align="left">
                <bold>Patient&#x2019;s values</bold>
              </th>
              <th align="left">
                <bold>Laboratory parameters</bold>
              </th>
              <th align="left">
                <bold>Patient&#x2019;s values</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="bottom">AST<hr/></td>
              <td align="left" valign="bottom">17 U/l<hr/></td>
              <td align="left" valign="bottom">Glu<hr/></td>
              <td align="left" valign="bottom">109&#xA0;mg/dl<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">ALT<hr/></td>
              <td align="left" valign="bottom">5 U/l<hr/></td>
              <td align="left" valign="bottom">CRP<hr/></td>
              <td align="left" valign="bottom">
                <bold>7.59&#xA0;mg/dl</bold>
                <hr/>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom">ALP<hr/></td>
              <td align="left" valign="bottom">171 U/l<hr/></td>
              <td align="left" valign="bottom">Lipase<hr/></td>
              <td align="left" valign="bottom">
                <bold>959 U/l</bold>
                <hr/>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom">&#x3B3;-GTP<hr/></td>
              <td align="left" valign="bottom">20 U/l<hr/></td>
              <td align="left" valign="bottom">WBC<hr/></td>
              <td align="left" valign="bottom">
                <bold>17,700/mm</bold>
                <sup>
<bold>3</bold>
</sup>
                <hr/>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom">T-Bil<hr/></td>
              <td align="left" valign="bottom">0.3&#xA0;mg/dl<hr/></td>
              <td align="left" valign="bottom">NEUTRO<hr/></td>
              <td align="left" valign="bottom">
                <bold>82.7%</bold>
                <hr/>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom">BUN<hr/></td>
              <td align="left" valign="bottom">
                <bold>53&#xA0;mg/dl</bold>
                <hr/>
              </td>
              <td align="left" valign="bottom">EOSINO<hr/></td>
              <td align="left" valign="bottom">0.0%<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Cre<hr/></td>
              <td align="left" valign="bottom">
                <bold>10.52&#xA0;mg/dl</bold>
                <hr/>
              </td>
              <td align="left" valign="bottom">BASO<hr/></td>
              <td align="left" valign="bottom">0.1%<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Na<hr/></td>
              <td align="left" valign="bottom">138&#xA0;mEq/l<hr/></td>
              <td align="left" valign="bottom">MoC<hr/></td>
              <td align="left" valign="bottom">8.8%<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">K<hr/></td>
              <td align="left" valign="bottom">4.7&#xA0;mEq/l<hr/></td>
              <td align="left" valign="bottom">LYMPHO<hr/></td>
              <td align="left" valign="bottom">8.4%<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Cl<hr/></td>
              <td align="left" valign="bottom">102&#xA0;mEq/l<hr/></td>
              <td align="left" valign="bottom">RBC<hr/></td>
              <td align="left" valign="bottom">373&#xA0;&#xD7;&#xA0;10<sup>4</sup>/mm<sup>3</sup><hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">CK<hr/></td>
              <td align="left" valign="bottom">72 U/l<hr/></td>
              <td align="left" valign="bottom">Hb<hr/></td>
              <td align="left" valign="bottom">11.4&#xA0;g/dl<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">AMY<hr/></td>
              <td align="left" valign="bottom">
                <bold>1,227 U/l</bold>
                <hr/>
              </td>
              <td align="left" valign="bottom">Ht<hr/></td>
              <td align="left" valign="bottom">35.8%<hr/></td>
            </tr>
            <tr>
              <td align="left">P-AMY</td>
              <td align="left">
                <bold>1,133 U/l</bold>
              </td>
              <td align="left">Plt</td>
              <td align="left">11.9&#xA0;&#xD7;&#xA0;10<sup>4</sup>/mm<sup>3</sup></td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p><italic>Abbreviations</italic>: AST, aspartate transaminase; ALT, alanine transaminase; ALP, alkaline phosphatase; &#x3B3;-GTP, &#x3B3;-glutamyl transpeptidase; T-Bil, total bilirubin; BUN, blood urea nitrogen; Cre, creatinine; Na, sodium; K, potassium; Cl, chloride; CK, creatine kinase; AMY, amylase; P-AMY, pancreatic-type amylase; Glu, glucose; CRP, C-reactive protein; WBC, white blood cells; NEUTRO, neutrophil; EOSINO, eosinophil; BASO, basophil; Moc, monocyte; LYMPHO, lymphocyte; RBC, red blood cells; Hb, hemoglobin; Ht, hematocrit; Plt, platelets.</p>
          <p>Numbers in bold type indicate abnormal value.</p>
        </table-wrap-foot>
      </table-wrap>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Abdominal computed tomography showing pancreatomegaly and an increased amount of peripancreatic fat.</p>
        </caption>
        <graphic xlink:href="1471-244X-14-93-1"/>
      </fig>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>The course of treatment with VPA and changes in serum amylase.</bold> Abbreviations: AMY, amylase; P-AMY, pancreatic-type amylase; VPA, sodium valproate.</p>
        </caption>
        <graphic xlink:href="1471-244X-14-93-2"/>
      </fig>
      <sec>
        <title>Discussion</title>
        <p>In 1979, Canfield et al. [<xref ref-type="bibr" rid="B2">2</xref>] and Batalden et al. [<xref ref-type="bibr" rid="B3">3</xref>] separately reported cases of acute pancreatitis caused by VPA. Since then, more than 100 such cases have appeared in the literature [<xref ref-type="bibr" rid="B4">4</xref>], although most cases involved epilepsy, and only two cases involved bipolar disorder [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Ng et al. reported a female patient with epilepsy who was administered VPA and developed pancreatitis during hemodialysis [<xref ref-type="bibr" rid="B7">7</xref>]. Since then, the similar types of cases that have been reported thus far were cases with epilepsy [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. To the best of our knowledge, the present report is the first case of VPA-induced pancreatitis in a patient with bipolar disorder who was also undergoing hemodialysis.</p>
        <p>Torelli et al. reported that the intermediate metabolites of VPA have toxic effects on pancreatic cells, and this is believed to be the main cause of VPA-induced pancreatitis [<xref ref-type="bibr" rid="B11">11</xref>], although the definite metabolite has not been revealed yet. VPA is primarily metabolized as a glucuronic acid-conjugated compound [<xref ref-type="bibr" rid="B10">10</xref>]; however, several types of intermediate metabolites other than the glucuronic acid-conjugated compound are found in normal human urine. One possible etiology is that patients with renal failure are prone to pancreatitis because these intermediate metabolites accumulate due to renal failure leading to pancreatic cell damage.</p>
        <p>When considering regimens of other mood stabilizers for patients with bipolar disorder who have renal failure, lithium carbonate does not bind to the plasma protein, and more than 95% of lithium is excreted by the kidney [<xref ref-type="bibr" rid="B12">12</xref>]. Therefore, patients with renal dysfunction would be expected to accumulate lithium and show a decline in renal function and serious lithium toxicity. In addition, maintaining adequate blood levels of lithium to achieve a response may be difficult because of the high dialyzability of lithium [<xref ref-type="bibr" rid="B13">13</xref>]. For administration of carbamazepine (CBZ), close monitoring of patients with renal failure is believed to be required because toxicity can readily occur as a result of accumulation of toxic CBZ-hydroxylated metabolites due to low albuminemia and inhibition of CBZ binding to the serum protein by a uremic toxin [<xref ref-type="bibr" rid="B14">14</xref>]. Therefore, using other mood stabilizers such as these for patients on hemodialysis requires close therapeutic drug monitoring. Physicians should be alert to signs of serious toxicity and the onset of adverse effects.</p>
        <p>VPA is primarily metabolized by the liver; therefore, the management of the dose and blood level should be relatively easy because of its low dialyzability [<xref ref-type="bibr" rid="B15">15</xref>]. Therefore, VPA seems to be safe even for patients on hemodialysis. However, as in the present case, we must be cognizant of the possibility of serious adverse effects such as pancreatitis.</p>
      </sec>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusion</title>
      <p>When prescribing a mood stabilizer to patients with bipolar disorder on hemodialysis, VPA is believed to be safer than other mood stabilizers. However, it is necessary to monitor patients closely for serious adverse effects such as pancreatitis.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>The patient has given written consent for publication of this case report.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>HO produced the initial draft including interpretation of the case findings. TS, AO, YO and KS critically revised the draft. All authors have read and given final approval to the version to be published.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-244X/14/93/prepub">http://www.biomedcentral.com/1471-244X/14/93/prepub</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgment</title>
      <p>The authors wish to thank the colleagues of their department at Dokkyo Medical University.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Moreiras Plaza</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rodr&#xED;guez Goyanes</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Cui&#xF1;a</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Alonso</surname>
            <given-names>R</given-names>
          </name>
          <article-title>On the toxicity of valproic-acid</article-title>
          <source>Clin Nephrol</source>
          <year>1999</year>
          <volume>51</volume>
          <fpage>187</fpage>
          <lpage>189</lpage>
          <pub-id pub-id-type="pmid">10099893</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Camfield</surname>
            <given-names>PR</given-names>
          </name>
          <name>
            <surname>Bagnell</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Camfield</surname>
            <given-names>CS</given-names>
          </name>
          <name>
            <surname>Tibbles</surname>
            <given-names>JA</given-names>
          </name>
          <article-title>Pancreatitis due to valproic acid</article-title>
          <source>Lancet</source>
          <year>1979</year>
          <volume>2; 1</volume>
          <fpage>1198</fpage>
          <lpage>1199</lpage>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Batalden</surname>
            <given-names>PB</given-names>
          </name>
          <name>
            <surname>Van Dyne</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>Cloyd</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Pancreatitis associated with valproic acid therapy</article-title>
          <source>Pediatrics</source>
          <year>1979</year>
          <volume>64</volume>
          <fpage>520</fpage>
          <lpage>522</lpage>
          <pub-id pub-id-type="pmid">114966</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Santos</surname>
            <given-names>BL</given-names>
          </name>
          <name>
            <surname>Fernandes</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Neves</surname>
            <given-names>FF</given-names>
          </name>
          <article-title>Valproic acid-induced pancreatitis in an adult</article-title>
          <source>Arq Neuropsiquiatr</source>
          <year>2010</year>
          <volume>68</volume>
          <fpage>135</fpage>
          <lpage>136</lpage>
          <pub-id pub-id-type="doi">10.1590/S0004-282X2010000100029</pub-id>
          <pub-id pub-id-type="pmid">20339670</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Buzan</surname>
            <given-names>RD</given-names>
          </name>
          <name>
            <surname>Firestone</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Thomas</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dubovsky</surname>
            <given-names>SL</given-names>
          </name>
          <article-title>Valproate-associated pancreatitis and cholecystitis in six mentally retarded adults</article-title>
          <source>J Clin Psychiatry</source>
          <year>1995</year>
          <volume>56</volume>
          <fpage>529</fpage>
          <lpage>532</lpage>
          <pub-id pub-id-type="pmid">7592507</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Laghate</surname>
            <given-names>VD</given-names>
          </name>
          <name>
            <surname>Gupta</surname>
            <given-names>SB</given-names>
          </name>
          <article-title>Acute pancreatitis and diabetic ketoacidosis in non-diabetic person while on treatment with sodium valproate, chlorpromazine and haloperidol</article-title>
          <source>J Assoc Physicians India</source>
          <year>2004</year>
          <volume>52</volume>
          <fpage>257</fpage>
          <lpage>258</lpage>
          <pub-id pub-id-type="pmid">15636323</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ng</surname>
            <given-names>JY</given-names>
          </name>
          <name>
            <surname>Disney</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Jones</surname>
            <given-names>TE</given-names>
          </name>
          <name>
            <surname>Purdie</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Acute pancreatitis and sodium valproate</article-title>
          <source>Med J Aust</source>
          <year>1982</year>
          <volume>2</volume>
          <fpage>362</fpage>
          <pub-id pub-id-type="pmid">6815441</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ford</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Portman</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Lum</surname>
            <given-names>GM</given-names>
          </name>
          <article-title>Pancreatitis in children on chronic dialysis treated with valproic acid</article-title>
          <source>Pediatr Nephrol</source>
          <year>1990</year>
          <volume>4</volume>
          <fpage>259</fpage>
          <lpage>261</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00857671</pub-id>
          <pub-id pub-id-type="pmid">2119213</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kondo</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Oba</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Obata</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Takahashi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Teraoka</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Toma</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Agishi</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Ota</surname>
            <given-names>K</given-names>
          </name>
          <article-title>A case of acute pancreatitis in a hemodialysis patient during the valproic therapy</article-title>
          <source>Kidney Dial</source>
          <year>1993</year>
          <volume>34</volume>
          <fpage>297</fpage>
          <lpage>300</lpage>
          <comment>(In Japanese)</comment>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kamijo</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Sato</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Yanagizawa</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kishi</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Acute pancreatitis and hyperammonemia in a hemodialysis patient during valproic acid therapy: a case report</article-title>
          <source>J Jpn Soc Dial Ther</source>
          <year>1994</year>
          <volume>27</volume>
          <fpage>53</fpage>
          <lpage>57</lpage>
          <comment>(In Japanese)</comment>
          <pub-id pub-id-type="doi">10.4009/jsdt.27.53</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Torelli</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Galeone</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Lamontanara</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Serum amylase in patients treated with sodium valproate</article-title>
          <source>Acta Neurol (Napoli)</source>
          <year>1982</year>
          <volume>4</volume>
          <fpage>455</fpage>
          <lpage>459</lpage>
          <pub-id pub-id-type="pmid">6187185</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Groth</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Prellwitz</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>J&#xE4;hnchen</surname>
            <given-names>E</given-names>
          </name>
          <article-title>Estimation of pharmacokinetic parameters of lithium from saliva and urine</article-title>
          <source>Clin Pharmacol Ther</source>
          <year>1974</year>
          <volume>16</volume>
          <fpage>490</fpage>
          <lpage>498</lpage>
          <pub-id pub-id-type="pmid">4472105</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sato</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Yamazumi</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Pharmacotherapy of psychiatric omplications following chronic renal failure</article-title>
          <source>Jpn J Neuropsychopharmacol</source>
          <year>1984</year>
          <volume>6</volume>
          <fpage>507</fpage>
          <lpage>515</lpage>
          <comment>(In Japanese)</comment>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>McLaren</surname>
            <given-names>KD</given-names>
          </name>
          <name>
            <surname>Marangell</surname>
            <given-names>LB</given-names>
          </name>
          <article-title>Special considerations in the treatment of patients with bipolar disorder and medical co-morbidities</article-title>
          <source>Ann Gen Hosp Psychiatry</source>
          <year>2004</year>
          <volume>3</volume>
          <fpage>7</fpage>
          <pub-id pub-id-type="doi">10.1186/1475-2832-3-7</pub-id>
          <pub-id pub-id-type="pmid">15104799</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gupta</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Annadatha</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Treating bipolar disorder in patients with renal failure having haemodialysis: two case reports</article-title>
          <source>Clin Pract Epidemiol Ment Health</source>
          <year>2008</year>
          <volume>4</volume>
          <fpage>21</fpage>
          <comment>doi:10.1186/1745-0179-4-21</comment>
          <pub-id pub-id-type="doi">10.1186/1745-0179-4-21</pub-id>
          <pub-id pub-id-type="pmid">18655726</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
